3Billion Inc is a Korea-based company principally engaged in the provision of genetic testing services. The Company is principally engaged in the provision of rare genetic disease diagnostic testing services. The Company is also engaged in the research and development of technology that automatically reads the pathogenicity of numerous genetic variants found in the genome.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	₩5,350.00	+3.08%	69,387
27/08/26	₩5,190.00	-4.07%	186,221
26/08/26	₩5,410.00	0.00%	51,563
25/08/26	₩5,410.00	-0.55%	70,817
24/08/26	₩5,440.00	+0.37%	67,644

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 28/08/2026			5-day change	1st Jan Change
5,350.00 ^KRW	+3.08%		-7.44%	-70.65%

06-01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
05-13	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI

Market Cap	170B 124M 106M 99.8M 91.1M 172M 11.81B 172M 1.18B 462M 5.96B 464M 454M 19.76B	P/E 2025	-107x	P/E 2026 *	-
Enterprise Value	153M 111K 95.88K 89.9K 82.06K 155K 10.63M 155K 1.07M 416K 5.37M 418K 409K 17.8M	EV / Sales 2025	49x	EV / Sales 2026 *	-
Free-Float	75.48%	Yield 2025 *	-	Yield 2026 *	-

06-01	3billion Launches 3B-NEO, Genomic Newborn Screening Service Covering 595 Clinically Actionable Genetic Conditions	CI
05-13	3billion, Inc. announced that it has received KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd.	CI
04-23	3billion, Inc. announced that it expects to receive KRW 29.999999888 billion in funding from Meritz Securities Co., Ltd., Wonik Investment Partners Co., Ltd. and other investors.	CI
04-09	3Billion Inc wins 955 million won order	RE
03-23	3billion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/03/25	3Billion Inc Wins 655 Million Won Order	RE

1 day	+3.08%
1 week	-7.44%
Current month	+4.09%
1 month	-6.63%
3 months	-45.30%
6 months	-62.98%
Current year	-70.65%

3billion, Inc. Stock

Stocks

A394800

KR7394800007

Biotechnology & Medical Research

Valuation : 3billion, Inc.

Chart: 3billion, Inc.

Latest news : 3billion, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : 3billion, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	5,100	5,530
1 month	4,260	6,660
Current year	4,260	18,690
1 year	4,260	20,100
3 years	3,025	20,100
5 years	3,025	20,100
10 years	3,025	20,100

Manager	Title	Age	Since
Chang-Won Geum CEO	Chief Executive Officer	45	10/10/2016
Soon-Il Park DFI	Director of Finance/CFO	46	01/10/2020
Jeong-Seol Lee CTO	Chief Tech/Sci/R&D Officer	46	01/08/2018

Director	Title	Age	Since
Chang-Won Geum BRD	Director/Board Member	45	10/10/2016
Se-Hwan Kim BRD	Director/Board Member	44	10/10/2016
Ki-Hyeon Kang BRD	Director/Board Member	44	18/11/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/4/25	Soon-Il Park	Others	Chief Financial Officer	44,000	0.1387%
7/3/25	Soon-Il Park	Fiscal year	Chief Financial Officer	40,000	0.1262%
7/3/25	Ki-hyun Kang	Fiscal year		10,000	0.0316%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
3BILLION, INC.	+3.08%	-7.44%	-9.01%	-	120M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-3.95%	-2.21%	+90.95%	+311.91%	4.22B
IOVANCE BIOTHERAPEUTICS, INC.	-2.72%	-3.02%	+260.54%	+31.37%	3.74B
VERACYTE, INC.	-3.30%	+3.55%	+46.28%	+74.89%	3.64B
CAREDX, INC.	-4.22%	+3.16%	+282.49%	+465.97%	2.71B
BGI GENOMICS CO., LTD.	-3.09%	-9.73%	-27.62%	-23.20%	2.33B
FREENOME, INC.	+7.68%	+3.18%	+32.26%	-	1.5B
MARAVAI LIFESCIENCES HOLDINGS, INC.	-7.29%	-10.07%	+226.47%	-24.71%	1.25B
SEEGENE, INC.	+11.76%	+14.08%	+37.91%	+65.05%	1.05B
CURIOX BIOSYSTEMS CO., LTD	-2.87%	+20.89%	+26.40%	+178.15%	694M
Average	-0.52%	+2.17%	+96.67%	+134.93%	2.12B
Weighted average by Cap.	-2.15%	+2.28%	+123.11%	+156.67%

	2025	2026 *
Net sales	10.8B 7.84M 6.75M 6.33M 5.78M 10.89M 749M 10.92M 75.11M 29.31M 378M 29.42M 28.78M 1.25B	-
Net income	-5.8B -4.21M -3.63M -3.4M -3.1M -5.85M -402M -5.87M -40.34M -15.74M -203M -15.8M -15.46M -673M	-
Net Debt	-16.9B -12.26M -10.57M -9.91M -9.04M -17.04M -1.17B -17.09M -118M -45.86M -592M -46.04M -45.04M -1.96B	-